Reversal of elevated international normalized ratios and bleeding with low-dose recombinant activated factor VII in patients receiving warfarin.

Study Objective: To assess the effectiveness of using low-dose recombinant activated factor VII (rFVIIa) to reverse the effects of warfarin in critically ill patients with major bleeding events.

Design: Prospective observational study.

Setting: Intensive care unit of a 500-bed university-affiliated hospital.